As discussed earlier, Sage Therapeutics (SAGE) is focused on the development of products for the treatment of life-threatening central nervous system (or CNS) disorders. The products under development include SAGE-718 and SAGE-904.
The above chart shows details about products under development in the NMDA receptor program.
There are three types of ionotropic glutamate receptors:
- NMDA (or N-methyl-D-aspartate) receptor
- Kainic acid receptor
- AMPA (Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor
Sage Therapeutics has developed products such as SAGE-718 and SAGE-904 that target the NMDA receptor.
SAGE-718, the first compound outside the GABA receptor program from Sage, is an oxysterol-based positive allosteric modulator of the NMDA receptor.
SAGE-718 is under phase one clinical study for the treatment of cerebrosterol deficit disorders and also for anti-NMDA receptor encephalitis and other indications that involve NMDA receptor hypofunction.
SAGE-718 was developed as a once-daily dosage compound. The phase one single ascending dose (or SAD) trial is a double-blind, placebo-controlled study to evaluate the safety, tolerance, and pharmacokinetics as well as pharmacodynamics effects of the drug when administered orally once a day to adults. Sage plans to begin the phase one multiple ascending dose trial for the evaluation of SAGE-718 in 2018.
SAGE-904 is the second compound developed by Sage using its NMDA receptor program. SAGE-904 is a positive allosteric modulator, but the drug has a differentiated pharmacologic and pharmacokinetic profile as compared to SAGE-718. Sage has initiated the IND-enabling studies for SAGE-904.